Literature DB >> 27995387

Noncoding RNAs in Heart Failure.

Seema Dangwal1, Katharina Schimmel1, Ariana Foinquinos1, Ke Xiao1, Thomas Thum2.   

Abstract

Heart failure is a major contributor to the healthcare burden and mortality worldwide. Current treatment strategies are able to slow down the transition of healthy heart into the failing one; nevertheless better understanding of the complex genetic regulation of maladaptive remodeling in the failing heart is essential for new drug discovery. Noncoding RNAs are key epigenetic regulators of cardiac gene expression and thus significantly influence cardiac homeostasis and functions.In this chapter we will discuss characteristics of noncoding RNAs, especially miRNAs, long noncoding RNAs, and circular RNAs, and review recent evidences proving their profound involvement during different stages of heart failure progression. Several open questions still prevent the extensive use of noncoding RNA-modulating therapies in clinics; yet they are becoming an attractive target to define novel regulatory mechanisms in the heart. In-depth study of their interaction with gene networks will refine our current view of heart failure and revolutionize the drug development in coming years.

Entities:  

Keywords:  Circular RNA; Heart failure; Long noncoding RNAs; miRNAs; ncRNA therapy

Mesh:

Substances:

Year:  2017        PMID: 27995387     DOI: 10.1007/164_2016_99

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  17 in total

Review 1.  Uncovering epigenetic landscape: a new path for biomarkers identification and drug development.

Authors:  Daiane Teixeira de Oliveira; Renata Guerra-Sá
Journal:  Mol Biol Rep       Date:  2020-10-21       Impact factor: 2.316

Review 2.  Noncoding RNAs: potential regulators in cardioncology.

Authors:  Shambhabi Chatterjee; Shashi Kumar Gupta; Christian Bär; Thomas Thum
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-11-09       Impact factor: 4.733

3.  Exploring biomarkers and therapeutic targets for pressure overload induced heart failure based on microarray data.

Authors:  Yongli He; Zhe Feng; Jianjun Lu; Rui Wang; Cheng Huang; Yingling Zhou
Journal:  Cardiovasc Diagn Ther       Date:  2020-10

4.  LINC00941 promoted in vitro progression and glycolysis of laryngocarcinoma by upregulating PKM via activating the PI3K/AKT/mTOR signaling pathway.

Authors:  Zhihai Li; Qiaozhi Jin; Yana Sun
Journal:  J Clin Lab Anal       Date:  2022-05-19       Impact factor: 3.124

Review 5.  Overview of noncoding RNAs involved in the osteogenic differentiation of periodontal ligament stem cells.

Authors:  Wei Qiu; Bu-Ling Wu; Fu-Chun Fang
Journal:  World J Stem Cells       Date:  2020-04-26       Impact factor: 5.326

6.  Marked disparity of microRNA modulation by cGMP-selective PDE5 versus PDE9 inhibitors in heart disease.

Authors:  Kristen M Kokkonen-Simon; Amir Saberi; Taishi Nakamura; Mark J Ranek; Guangshuo Zhu; Djahida Bedja; Michaela Kuhn; Marc K Halushka; Dong Ik Lee; David A Kass
Journal:  JCI Insight       Date:  2018-08-09

7.  Silencing long non-coding RNA, differentiation antagonizing non-protein coding RNA promotes apoptosis and inhibits tumor growth in colon cancer.

Authors:  Xiao-Jin Yang; Jing-Jing Zhao; Wei-Jun Chen; Gen-Gen Zhang; Wei Wang; Han-Chuan Tao
Journal:  Oncol Lett       Date:  2018-06-28       Impact factor: 2.967

Review 8.  Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers.

Authors:  Alexander E Berezin; Alexander A Berezin
Journal:  Dis Markers       Date:  2020-06-12       Impact factor: 3.434

Review 9.  Significance of non-coding circular RNAs and micro RNAs in the pathogenesis of cardiovascular diseases.

Authors:  Guoan Zhao
Journal:  J Med Genet       Date:  2018-09-03       Impact factor: 6.318

Review 10.  The Function and Therapeutic Potential of Long Non-coding RNAs in Cardiovascular Development and Disease.

Authors:  Clarissa P C Gomes; Helen Spencer; Kerrie L Ford; Lauriane Y M Michel; Andrew H Baker; Costanza Emanueli; Jean-Luc Balligand; Yvan Devaux
Journal:  Mol Ther Nucleic Acids       Date:  2017-07-28       Impact factor: 8.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.